Bio-Thera Solutions, Ltd.

SHSE:688177 Stock Report

Market Cap: CN¥8.3b

Bio-Thera Solutions Valuation

Is 688177 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688177 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688177 (CN¥20.08) is trading below our estimate of fair value (CN¥77.81)

Significantly Below Fair Value: 688177 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688177?

Key metric: As 688177 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 688177. This is calculated by dividing 688177's market cap by their current revenue.
What is 688177's PS Ratio?
PS Ratio10.1x
SalesCN¥825.18m
Market CapCN¥8.31b

Price to Sales Ratio vs Peers

How does 688177's PS Ratio compare to its peers?

The above table shows the PS ratio for 688177 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6x
300406 Beijing Strong BiotechnologiesInc
4.7x19.8%CN¥8.2b
600645 Vcanbio Cell & Gene Engineering
5.7x9.3%CN¥9.1b
600201 Jinyu Bio-technology
6x23.3%CN¥8.0b
300685 Amoy Diagnostics
7.8x20.0%CN¥9.3b
688177 Bio-Thera Solutions
10.1x24.0%CN¥8.3b

Price-To-Sales vs Peers: 688177 is expensive based on its Price-To-Sales Ratio (10.1x) compared to the peer average (6x).

Price to Sales Ratio vs Industry

How does 688177's PS Ratio compare vs other companies in the CN Biotechs Industry?

1 CompanyPrice / SalesEstimated GrowthMarket Cap
603716 Thalys Medical Technology Group
0.7xn/aUS$191.92m
No more companies available in this PS range
688177 10.1xIndustry Avg. 7.0xNo. of Companies10PS048121620+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 688177 is expensive based on its Price-To-Sales Ratio (10.1x) compared to the CN Biotechs industry average (7x).

Price to Sales Ratio vs Fair Ratio

What is 688177's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688177 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.1x
Fair PS Ratio6.5x

Price-To-Sales vs Fair Ratio: 688177 is expensive based on its Price-To-Sales Ratio (10.1x) compared to the estimated Fair Price-To-Sales Ratio (6.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 688177 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥20.08
CN¥31.00
+54.4%
19.4%CN¥37.00CN¥25.00n/a2
Dec ’25CN¥21.65
CN¥31.00
+43.2%
19.4%CN¥37.00CN¥25.00n/a2
Nov ’25CN¥22.54
CN¥31.00
+37.5%
19.4%CN¥37.00CN¥25.00n/a2
Oct ’25CN¥25.51
CN¥31.00
+21.5%
19.4%CN¥37.00CN¥25.00n/a2
Sep ’25CN¥19.96
CN¥38.00
+90.4%
34.2%CN¥51.00CN¥25.00n/a2
Aug ’25CN¥21.55
CN¥42.10
+95.4%
21.1%CN¥51.00CN¥33.20n/a2
Jul ’25CN¥21.08
CN¥42.10
+99.7%
21.1%CN¥51.00CN¥33.20n/a2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 20:46
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bio-Thera Solutions, Ltd. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yanyin ZhuChina International Capital Corporation Limited
Shitong HanCitic Securities Co., Ltd.
Yinglan ShuHaitong International Research Limited